Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease

Aurora Barberá; Trenton M. White; Anish K. Arora; Linda Henry; Jeffrey V. Lazarus; Zobair M. Younossi

doi:10.1055/a-2435-2091

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2025; 45(02): 210-220
DOI: 10.1055/a-2435-2091

Review Article

Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease

Aurora Barberá

¹The Global NASH Council, Washington, District of Columbia

²Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain

,

Trenton M. White

²Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain

,

Anish K. Arora

³Department of Family and Community Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

,

Linda Henry

¹The Global NASH Council, Washington, District of Columbia

⁴Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia

,

Jeffrey V. Lazarus

¹The Global NASH Council, Washington, District of Columbia

²Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain

⁵CUNY Graduate School of Public Health and Health Policy, New York City, New York

,

Zobair M. Younossi

¹The Global NASH Council, Washington, District of Columbia

⁴Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia

⁶Center for Outcomes Research in Liver Disease (CORLD), Washington, District of Columbia

› Institutsangaben

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and can progress to serious complications, including metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Predisposing risk factors for MASH include obesity, type 2 diabetes, dyslipidemia, and metabolic syndrome. Patients with MASH often experience significant impairments in their health-related quality of life and other patient-reported outcomes (PROs), particularly in physical functioning domains, fatigue, and vitality. Incorporating PROs offers valuable insights into patients' perspectives on their symptoms, treatment efficacy, and overall well-being, thereby guiding more holistic and patient-centered care strategies. This review aims to investigate the utilization of patient-reported outcome measures (PROMs) in the context of MASLD and MASH care, identify which PROMs are employed, and summarize the outcomes reported.

Keywords

MASH - quality of life - MASLD - HRQoL - person-centered care

Volltext

Referenzen

References
1 Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023; 77 (04) 1335-1347
2 Rinella ME, Lazarus JV, Ratziu V. et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023; 79 (06) 1542-1556
3 Younossi ZM, Zelber-Sagi S, Henry L, Gerber LH. Lifestyle interventions in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2023; 20 (11) 708-722
4 Lazarus JV, Mark HE, Anstee QM. et al; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2022; 19 (01) 60-78
5 Fitzmaurice C, Akinyemiju TF, Al Lami FH. et al; Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol 2018; 4 (11) 1553-1568
6 Sayiner M, Arshad T, Golabi P, Paik J, Farhat F, Younossi ZM. Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population. Hepatol Int 2020; 14 (04) 556-566
7 Golabi P, Gerber L, Paik JM, Deshpande R, de Avila L, Younossi ZM. Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease. JHEP Rep Innov Hepatol 2020; 2 (06) 100171
8 Mantovani A, Petracca G, Beatrice G. et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut 2022; 71 (04) 778-788
9 Schattenberg JM, Lazarus JV, Newsome PN. et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: a cost-of-illness analysis. Liver Int 2021; 41 (06) 1227-1242
10 Younossi ZM, Blissett D, Blissett R. et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016; 64 (05) 1577-1586
11 Draft. Posters for EASL 2024. Draft Editors S.L: 2024 Accessed July 23, 2024 at:
12 Younossi Z, Aggarwal P, Shrestha I. et al. The burden of non-alcoholic steatohepatitis: a systematic review of health-related quality of life and patient-reported outcomes. JHEP Rep Innov Hepatol 2022; 4 (09) 100525
13 Lazarus JV, Mark HE, Allen AM. et al; Healthy Livers, Healthy Lives Collaborators. A global research priority agenda to advance public health responses to fatty liver disease. J Hepatol 2023; 79 (03) 618-634
14 Schattenberg JM, Allen AM, Jarvis H. et al. A multistakeholder approach to innovations in NAFLD care. Commun Med (Lond) 2023; 3 (01) 1
15 Mansour MHH, Pokhrel S, Anokye N. Effectiveness of integrated care interventions for patients with long-term conditions: a review of systematic reviews. Integr Healthc J 2022; 4 (01) e000083
16 Younossi ZM. Patient-reported outcomes and the economic effects of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: the value proposition. Hepatology 2018; 68 (06) 2405-2412
17 Kall M, Marcellin F, Harding R, Lazarus JV, Carrieri P. Patient-reported outcomes to enhance person-centred HIV care. Lancet HIV 2020; 7 (01) e59-e68
18 Arora AK, Vicente S, Engler K. et al; ASAP Migrant Advisory Committee. Patient-reported outcomes and experiences of migrants enrolled in a multidisciplinary HIV clinic with rapid, free, and onsite treatment dispensation: the ‘ASAP’ study. AIDS Res Ther 2024; 21 (01) 40
19 Nano J, Carinci F, Okunade O. et al; Diabetes Working Group of the International Consortium for Health Outcomes Measurement (ICHOM). A standard set of person-centred outcomes for diabetes mellitus: results of an international and unified approach. Diabet Med 2020; 37 (12) 2009-2018
20 Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Am Soc Clin Oncol Educ Book 2016; 35 (36) 67-73
21 Post MWM. Definitions of quality of life: what has happened and how to move on. Top Spinal Cord Inj Rehabil 2014; 20 (03) 167-180
22 Brands MR, Gouw SC, Beestrum M, Cronin RM, Fijnvandraat K, Badawy SM. Patient-centered digital health records and their effects on health outcomes: systematic review. J Med Internet Res 2022; 24 (12) e43086
23 Doward LC, Gnanasakthy A, Baker MG. Patient reported outcomes: looking beyond the label claim. Health Qual Life Outcomes 2010; 8: 89
24 Younossi ZM, Yilmaz Y, Yu ML. et al; Global NASH Council. Clinical and patient-reported outcomes from patients with nonalcoholic fatty liver disease across the world: data from the global Non-Alcoholic Steatohepatitis (NASH)/Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. Clin Gastroenterol Hepatol 2022; 20 (10) 2296-2306.e6
25 David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB. NASH CRN Research Group. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009; 49 (06) 1904-1912
26 Sayiner M, Stepanova M, Pham H, Noor B, Walters M, Younossi ZM. Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenterol 2016; 3 (01) e000106
27 Younossi ZM, Anstee QM, Wai-Sun Wong V. et al. The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis. Gastroenterology 2021; 160 (05) 1608-1619.e13
28 Dan AA, Kallman JB, Wheeler A. et al. Health-related quality of life in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2007; 26 (06) 815-820
29 U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4: 79
30 Zang S, Chen J, Song Y. et al; Chinese NAFLD Clinical Research Network (CNAFLD CRN). Haptoglobin genotype and vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis in China: a multicenter, randomized, placebo-controlled trial design. Adv Ther 2018; 35 (02) 218-231
31 Sun Y, Chen G, Chen S, Wang Y, Hu Y, Zhao Y. Efficacy and safety of Jian-Pi Huo-Xue granule for non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled trial. Trials 2022; 23 (01) 455
32 Yamamura S, Nakano D, Hashida R. et al. Patient-reported outcomes in patients with non-alcoholic fatty liver disease: a narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2021; 36 (03) 629-636
33 Chawla KS, Talwalkar JA, Keach JC, Malinchoc M, Lindor KD, Jorgensen R. Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH). BMJ Open Gastroenterol 2016; 3 (01) e000069
34 Aggio D, Gallop K, Wittrup-Jensen V, Farsani SF, Lloyd AJ. Estimating utility values for non-alcoholic steatohepatitis health states: a discrete choice experiment. J Comp Eff Res 2024; 13 (02) e230033
35 Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999; 45 (02) 295-300
36 Younossi ZM, Stepanova M, Henry L. Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in clinical trials of patients with chronic hepatitis C. Value Health 2016; 19 (05) 544-551
37 Younossi ZM, Stepanova M, Younossi I, Racila A. Validation of Chronic Liver Disease Questionnaire for nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2019; 17 (10) 2093-2100.e3
38 Fishman J, Higgins V, Piercy J, Pike J. Cross-walk of the Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) and the EuroQol EQ-5D-5L in patients with NASH. Health Qual Life Outcomes 2023; 21 (01) 113
39 Younossi Z, Stepanova M, Younossi I, Racila A. Development and Validation of CLDQ-MASH: A disease Specific Health Related Quality of Life Instrument for Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH). Milan, Italy: ILC; 2024. (Poster)
40 Yilmaz Y, Toraman AE, Alp C. et al. Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study. Aliment Pharmacol Ther 2023; 57 (02) 215-223
41 Shea S, Lionis C, Kite C. et al. Non-alcoholic fatty liver disease and coexisting depression, anxiety and/or stress in adults: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2024; 15: 1357664
42 Golubeva JA, Sheptulina AF, Yafarova AA, Mamutova EM, Kiselev AR, Drapkina OM. Reduced quality of life in patients with non-alcoholic fatty liver disease may be associated with depression and fatigue. Healthcare (Basel) 2022; 10 (09) 1699
43 Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA. Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life. Clin Gastroenterol Hepatol 2022; 20 (06) 1354-1361.e7
44 Younossi ZM, Stepanova M, Racila A. et al. Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis. Hepatology 2024;
45 Romero-Gómez M, Armstrong MJ, Funuyet-Salas J. et al. Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: a randomised trial. Aliment Pharmacol Ther 2023; 58 (04) 395-403
46 Younossi ZM, Stepanova M, Nader F. et al; RandomizEd Global Phase 3 Study to Evaluate the Impact on NASH with FibRosis of Obeticholic Acid TreatmEnt (REGENERATE) Study Investigators. Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-month interim analysis. Clin Gastroenterol Hepatol 2022; 20 (09) 2050-2058.e12
47 Younossi ZM, Kremer AE, Swain MG. et al. Assessment of fatigue and its impact in chronic liver disease. J Hepatol 2024; 81 (04) 726-742
48 Doward LC, Balp MM, Twiss J. et al. Development of a patient-reported outcome measure for non-alcoholic steatohepatitis (NASH-CHECK): results of a qualitative study. Patient 2021; 14 (05) 533-543
49 Twiss J, Whalley D, Doward L. et al. Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis. J Patient Rep Outcomes 2023; 7 (01) 69
50 Nguyen H, Butow P, Dhillon H, Sundaresan P. A review of the barriers to using patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs) in routine cancer care. J Med Radiat Sci 2021; 68 (02) 186-195
51 Long C, Beres LK, Wu AW, Giladi AM. Patient-level barriers and facilitators to completion of patient-reported outcomes measures. Qual Life Res 2022; 31 (06) 1711-1718
52 Philpot LM, Barnes SA, Brown RM. et al. Barriers and benefits to the use of patient-reported outcome measures in routine clinical care: a qualitative study. Am J Med Qual 2018; 33 (04) 359-364
53 Bussone A, Stumpf S, Bird J. Disclose-it-yourself: security and privacy for people living with HIV. InCHI EA'16: Proceedings of the 2016 ACM annual conference on Human Factors in Computing Systems Extended Abstracts 2016. May (pp. 1–4). 2016
54 Jacomet C, Ologeanu-Taddei R, Prouteau J. et al. Adoption and attitudes of eHealth among people living with HIV and their physicians: Online Multicenter Questionnaire Study. JMIR Mhealth Uhealth 2020; 8 (04) e16140
55 Nelson EC, Eftimovska E, Lind C, Hager A, Wasson JH, Lindblad S. Patient reported outcome measures in practice. BMJ 2015; 350: g7818
56 Brundage MD, Wu AW, Rivera YM, Snyder C. Promoting effective use of patient-reported outcomes in clinical practice: themes from a “Methods Tool kit” paper series. J Clin Epidemiol 2020; 122: 153-159
57 Hsiao CJ, Dymek C, Kim B, Russell B. Advancing the use of patient-reported outcomes in practice: understanding challenges, opportunities, and the potential of health information technology. Qual Life Res 2019; 28 (06) 1575-1583
58 Shen N, Strauss J, Silver M, Carter-Langford A, Wiljer D. The eHealth trust model: a patient privacy research framework. Stud Health Technol Inform 2019; 257: 382-387
59 Schwimmer JB, Middleton MS, Deutsch R, Lavine JE. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2005; 21 (07) 871-879
60 Kistler KD, Molleston J, Unalp A, Abrams SH, Behling C, Schwimmer JB. Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2010; 31 (03) 396-406
61 Kerkar N, D'Urso C, Van Nostrand K. et al. Psychosocial outcomes for children with nonalcoholic fatty liver disease over time and compared with obese controls. J Pediatr Gastroenterol Nutr 2013; 56 (01) 77-82
62 Mazzone L, Postorino V, De Peppo L. et al. Paediatric non-alcoholic fatty liver disease: impact on patients and mothers' quality of life. Hepat Mon 2013; 13 (03) e7871
63 Michel M, Labenz C, Anders M. et al. Effect of hepatic steatosis and associated metabolic comorbidities on health-related quality of life in people living with HIV. Hepatol Commun 2022; 6 (08) 2011-2021
64 Wernberg CW, Kjer MF, Grønkjaer LL, Jacobsen BG, Lauridsen MM. Steatotic liver disease is the most important somatic determinant of quality of life in patients with obesity: a cross-sectional study. Liver Int 2024; 44 (01) 191-201
65 Janota B, Adamek B, Szczepańska E, Biernacki K, Janczewska E. Lifestyle and quality of life of women diagnosed with hypothyroidism in the context of non-alcoholic fatty liver. Metabolites 2023; 13 (12) 1174
66 Younossi ZM, AlQahtani SA, Funuyet-Salas J. et al; Global NASH Council. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease. JHEP Rep Innov Hepatol 2024; 6 (07) 101066
67 Jawad MY, Meshkat S, Tabassum A. et al. The bidirectional association of nonalcoholic fatty liver disease with depression, bipolar disorder, and schizophrenia. CNS Spectr 2023; 28 (05) 541-560

Zusatzmaterial

Supplementary Material